[{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"OnabotulinumtoxinA","moa":"","graph1":"Urology","graph2":"Phase II","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Mitomycin","moa":"DNA Alkylation","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Pyelocalyceal solution","sponsorNew":"UroGen Pharma \/ RTW Investments","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ RTW Investments"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Neopharm Labs Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Mitomycin","moa":"DNA synthesis","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ Neopharm Labs Inc","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Neopharm Labs Inc"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Zalifrelimab","moa":"CTLA-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Zalifrelimab","moa":"TLR7","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA Alkylation","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA synthesis","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA synthesis","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ BofA Securities"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Medac","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"UroGen Pharma \/ UroGen Pharma","highestDevelopmentStatusID":"4","companyTruncated":"UroGen Pharma \/ UroGen Pharma"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"UroGen Pharma \/ TD Cowen","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ TD Cowen"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"UroGen Pharma \/ TD Cowen","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ TD Cowen"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Zalifrelimab","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"UroGen Pharma \/ MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"UroGen Pharma \/ MD Anderson Cancer Center"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase IV","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"IconOVir Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Acquisition","leadProduct":"ICVB-1042","moa":"E2F1","graph1":"Oncology","graph2":"Phase I","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UroGen Pharma \/ UroGen Pharma","highestDevelopmentStatusID":"6","companyTruncated":"UroGen Pharma \/ UroGen Pharma"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by UroGen Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : UroGen expand its oncology pipeline portfolio through the acquisition of assets relating to a next-gen oncolytic virus ICVB-1042 from IconOVir Bio.

Product Name : ICVB-1042

Product Type : Microorganism

Upfront Cash : Undisclosed

February 20, 2025

Lead Product(s) : ICVB-1042

Therapeutic Area : Oncology

Highest Development Status : Phase I

Recipient : IconOVir Bio

Deal Size : Undisclosed

Deal Type : Acquisition

blank

02

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : UGN-102 (mitomycin) is a DNA synthesis inhibitor which is currently being evaluated in phase 3 clinical trials for the treatment of low-grade, intermediate-risk non-muscle invasive bladder cancer.

Product Name : UGN-102

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

February 14, 2025

Lead Product(s) : Mitomycin

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

03

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : Jelmyto® (mitomycin) is a FDA approved pyelocalyceal solution is a mitomycin-containing 4 mg mitomycin per mL gel indicated for primary chemoablative treatment of LG-UTUC in adults.

Product Name : Jelmyto

Product Type : Antibiotic

Upfront Cash : Inapplicable

January 22, 2025

Lead Product(s) : Mitomycin

Therapeutic Area : Oncology

Highest Development Status : Phase IV

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

04

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : UGN-102 (mitomycin) is a DNA synthesis inhibitor which is currently being evaluated in phase 3 clinical trials for the treatment of low-grade, intermediate-risk non-muscle invasive bladder cancer.

Product Name : UGN-102

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

December 05, 2024

Lead Product(s) : Mitomycin

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

05

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : Jelmyto® (mitomycin) is a FDA approved pyelocalyceal solution is a mitomycin-containing reverse thermal gel, indicated for primary chemoablative treatment of LG-UTUC in adults.

Product Name : Jelmyto

Product Type : Small molecule

Upfront Cash : Not Applicable

November 26, 2024

Lead Product(s) : Mitomycin

Therapeutic Area : Oncology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

06

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : UGN-102 (mitomycin) is a DNA synthesis inhibitor which is currently being evaluated in phase 3 clinical trials for the treatment of low-grade, intermediate-risk non-muscle invasive bladder cancer.

Product Name : UGN-102

Product Type : Small molecule

Upfront Cash : Not Applicable

October 15, 2024

Lead Product(s) : Mitomycin

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

07

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : UGN-103 is a next-generation novel mitomycin-based formulation, in development for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer

Product Name : UGN-103

Product Type : Small molecule

Upfront Cash : Not Applicable

October 02, 2024

Lead Product(s) : Mitomycin

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

08

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : UGN-102 (mitomycin) is a DNA synthesis inhibitor which is currently being evaluated in phase 3 clinical trials for the treatment of low-grade, intermediate-risk non-muscle invasive bladder cancer.

Product Name : UGN-102

Product Type : Small molecule

Upfront Cash : Not Applicable

August 14, 2024

Lead Product(s) : Mitomycin

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

09

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : The intend to use the net proceeds from the offering for the commercialization of Jelmyto (mitomycin). It is indicated for the treatment of low-grade upper tract urothelial cancer.

Product Name : Jelmyto

Product Type : Small molecule

Upfront Cash : Undisclosed

June 17, 2024

Lead Product(s) : Mitomycin

Therapeutic Area : Oncology

Highest Development Status : Approved

Sponsor : TD Cowen

Deal Size : $101.0 million

Deal Type : Public Offering

blank

10

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : The intend to use the net proceeds from this offering for the commercialization of Jelmyto (mitomycin). It is indicated for the treatment of low-grade upper tract urothelial cancer.

Product Name : Jelmyto

Product Type : Small molecule

Upfront Cash : Undisclosed

June 17, 2024

Lead Product(s) : Mitomycin

Therapeutic Area : Oncology

Highest Development Status : Approved

Sponsor : TD Cowen

Deal Size : $107.5 million

Deal Type : Public Offering

blank